MedTrace Logo

Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care

NCT04716985 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 700

Last updated 2022-04-05

No results posted yet for this study

Summary

Through its anti-inflammatory role, molecular hydrogen could have a beneficial effect in preventing the runaway inflammatory reactions that lead to complications of Covid-19.

This hypothesis is supported by numerous preclinical and theoretical arguments, as well as by some Chinese clinical studies (the Chinese guidelines for the management of Covid-19 recommend the inhalation of hydrogen), a recommendation whose interest has just been confirmed by a publication describing the very positive results of a clinical study in China.

Through its anti-inflammatory role, molecular hydrogen could have a beneficial effect in preventing the runaway inflammatory reactions that lead to complications of Covid-19.

The ingestion of water saturated with molecular hydrogen has been the subject of several clinical studies in other indications than Covid-19, and no side effects of this ingestion have been reported. A recent publication recommends initiating clinical trials using a hydrogen fortified beverage.

Conditions

Interventions

DIETARY_SUPPLEMENT

MOLECULAR HYDROGEN

Magnesium Tablet

DIETARY_SUPPLEMENT

PLACEBO MAGNESIUM

Magnesium carbonate tablet

Sponsors & Collaborators

  • Laboratoire TIMC-IMAG

    collaborator OTHER

  • DrinkHRW, British Columbia, Canada

    collaborator UNKNOWN

  • AGIR à Dom

    lead OTHER

Principal Investigators

  • Yoann Gaboreau, Dr · Laboratoire TIMC Equipe Themas

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-22
Primary Completion
2022-05-22
Completion
2023-05-22

Countries

  • France
  • Morocco
  • Serbia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04716985 on ClinicalTrials.gov